Evaluation of Efficacy of Fosfomycin for the Treatment of Patients with Lower Urinary Tract Infections (UTIs).

Introduction: Until now, there have been few investigations on the efficacy of fosfomycin in the treatment of patients with uncomplicated urinary tract infections (UTIs). The present study is aimed to examine how fosfomycin affects females with lower UTIs. Methods:A total of 200 female patients who visited the women's clinic at Amir-Al-Momenin Hospital between 2020 and 2021 were examined in the present study. Patients were randomly divided into two groups of 100 people each, with one group receiving fosfomycin (a single 3 g dose) and the other one receiving cephalexin (a five-day regimen at 0.5 g four times daily). Then, one week and one month after treatment, the patients underwent a urine culture test. The data were collected and further analyzed in SPSS statistics software version 26. Results:According to the study findings, the mean age of females suffering from lower UTI was 25.45 ± 5.85 years. Besides, the collected data revealed that 85.5% of females diagnosed with lower UTI had E. coli. In addition, the frequency of females with Staphylococcus saprophyticus, Proteus spp and Klebsiella were 9%, 3% and 2.5%, respectively. Also, the frequency of women with UTI for E. coli, Staphylococcus saprophyticus, Proteus spp and Klebsiella were 85.5%, 9%, 3.2% and 2.5%, respectively. One month after treatment, urine culture showed positive results in 98% of patients who were treated with fosfomycin and 95% of those who received cephalexin. Conclusion:Fosfomycin can be administrated to treat uncomplicated UTIs in women with a high level of confidence, as an alternative to cephalexin.